ImmunityBio’s (IBRX) “Buy” Rating Reaffirmed at HC Wainwright

Posted by Brenda Bartman on Oct 15th, 2026

ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Thursday, Marketbeat Ratings reports. They currently have a $15.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 47.41% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Piper Sandler reissued an “overweight” rating and set a $16.00 target price on shares of ImmunityBio in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of ImmunityBio in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, ImmunityBio presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Read Our Latest Report on IBRX

ImmunityBio Stock Performance

IBRX opened at $10.18 on Thursday. The stock has a market capitalization of $10.78 billion, a PE ratio of -10.44 and a beta of 0.02. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. The business’s 50 day moving average price is $8.48 and its 200 day moving average price is $7.94.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million. As a group, equities research analysts forecast that ImmunityBio will post -0.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the sale, the director owned 2,777,788 shares in the company, valued at $29,861,221. This represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total transaction of $851,088.00. Following the completion of the sale, the director owned 100,309 shares of the company’s stock, valued at $1,053,244.50. This trade represents a 44.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company’s stock.

Institutional Trading of ImmunityBio

Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Doliver Advisors LP raised its holdings in ImmunityBio by 110.0% during the 3rd quarter. Doliver Advisors LP now owns 210,000 shares of the company’s stock worth $1,982,000 after buying an additional 110,000 shares during the period. Hussman Strategic Advisors Inc. purchased a new stake in ImmunityBio during the second quarter valued at about $1,287,000. Tidal Investments LLC acquired a new position in shares of ImmunityBio in the second quarter worth about $2,207,000. SEB Asset Management AB acquired a new position in shares of ImmunityBio in the first quarter worth about $18,770,000. Finally, BlackRock Inc. increased its position in shares of ImmunityBio by 29.4% in the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after acquiring an additional 7,736,819 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

Positive Sentiment: The FDA expanded ANKTIVA’s approved use, in combination with BCG, to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) whose tumors are papillary-only. The broader label adds to the drug’s addressable patient population beyond its existing coverage of carcinoma in situ (CIS) disease and could support additional commercial revenue. FDA Expands ANKTIVA Approval
Positive Sentiment: The FDA decision came months ahead of the expected deadline, reducing regulatory uncertainty and allowing ImmunityBio to pursue the expanded market opportunity sooner. The approval expansion is the primary catalyst behind the stock’s recent strength. ImmunityBio Stock Climbs Thursday
Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and assigned a $15 price target, implying substantial upside from the stock’s referenced $9.91 level. The reaffirmation provides additional investor confidence following the FDA announcement.
Neutral Sentiment: Reports indicate that funds have increased their positions or bullish bets on IBRX, while Johnson & Johnson remains “on the lookout” for potential deals. However, no transaction involving ImmunityBio was announced, so this is speculative rather than a confirmed acquisition catalyst. Funds Raise Bets and J&J Deal Outlook

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.